Applying a Closed, Modular, Semi-Automated System to CAR T Cell Therapy Manufacturing
Cell-based chimeric antigen receptor (CAR) T cell therapies have rapidly advanced in recent years, with a variety of targets in clinical research and several FDA approved products already on the market. There has been tremendous effort to make CAR T cells more effective, safe and persistent when treating patients. On the manufacturing side, however, errors, lot-to-lot variation and contamination can be associated with open processes and manual handling of CAR T cells.
Watch this webinar to learn about:
- The various systems needed to develop and manufacture CAR T cell therapies
- The benefits of implementing closed, GMP-compliant, digitally connected solutions at earlier stages in CAR T cell therapy development
- The modular solutions that Thermo Fisher Scientific can provide to assist in the implementation of a CAR T cell therapy manufacturing process